Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.51 |
| ▸ | JUN | P05412 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569054 | 1.00 | ADORA1 (0.56) | ADORA1ADORA2AADORA2BMAPK10JUN | |
| SCHEMBL5492979 | 0.87 | RIPK2 (0.64) | ADORA1ADORA2AADORA2BMAPK10JUN | |
| SCHEMBL14569053 | 0.87 | RIPK2 (0.64) | ADORA1ADORA2AADORA2BMAPK10JUN | |
| SCHEMBL5488829 | 0.83 | MAPK10 (0.60) | ADORA1ADORA2AADORA2BMAPK10JUN | |
| SCHEMBL5488834 | 0.83 | MAPK10 (0.60) | ADORA1ADORA2AADORA2BMAPK10JUN | |
| SCHEMBL21416748 | 0.81 | MAPK10 (0.54) | ADORA1ADORA2AADORA2BMAPK10JUN | |
| SCHEMBL14568532 | 0.81 | MAPK10 (0.54) | ADORA1ADORA2AADORA2BMAPK10JUN | |
| SCHEMBL5492620 | 0.81 | MAPK10 (0.54) | ADORA1ADORA2AADORA2BMAPK10JUN | |
| SCHEMBL14569031 | 0.79 | LCK (0.54) | ADORA1ADORA2AADORA2BMAPK10JUN | |
| SCHEMBL5496767 | 0.79 | LCK (0.54) | ADORA1ADORA2AADORA2BMAPK10JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | claimed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | claimed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | claimed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | ADORA1 359/4885ADORA2A 267/4885ADORA2B 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.